ALSO NOTED: ImaRx files IPO; Cell Therapeutics gets fast track designation; and much more...

> ImaRx has filed for an initial public offering of three million shares designed to raise $25.9 million. The company listed an IPO price of $6.50 to $7.50 a share. Release

> Cell Therapeutics received fast track designation from the FDA for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed or refractory indolent non-Hodgkin's lymphoma. Release

> Mistral Pharma is acquiring CuraMedica, a privately-held Montreal company that owns the Canadian rights for Instillagel, a product licensed from Farco Pharma of Germany. Release

> Brookwood Pharmaceuticals and Targeted Technology Ventures have created a collaborative joint venture--Aeon Bioscience--which will work to develop a new drug-eluting stent. Release

> Spectrum Pharmaceuticals has entered an agreement to raise approximately $32 million. Release

And Finally… China's role in producing dangerous food and drugs has also been highlighted at BIO, which is hoping to use recent reports to help battle against reimportation. The New York Times helped with this timely expose on toxic syrup that has come from Chinese manufacturers. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.